SloMo2: Implementation, Effectiveness, and Cost-effectiveness Study

Launched by KING'S COLLEGE LONDON · Aug 20, 2024

Keywords

ClinConnect Summary

The SloMo2 trial is studying a new therapy called SloMo, designed to help people who experience paranoia, which is a common worry about being harmed by others. SloMo is a digital therapy that helps users slow down their thoughts and recognize when their worries might be getting out of hand. It has been developed with input from individuals who have experienced psychosis, as well as therapists and designers. The goal is to see if SloMo can be effectively and safely delivered by therapists in NHS services so that more people can access this helpful tool.

To participate in the trial, individuals must have a diagnosis of a psychotic disorder and be currently seeking help for feelings of paranoia. They should also be receiving care from mental health services and able to understand and consent to the therapy. During the trial, participants will work with trained therapists to use the SloMo app and attend therapy sessions that focus on managing their worries. Researchers will gather information about how well SloMo works, how much people enjoy it, and whether it can save costs for mental health services. This study aims to make SloMo a widely available option for those in need.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Meet criteria for ICD-10 psychosis diagnoses (F20-29, F30-39)
• • Seeking therapy for paranoia
• • In contact with secondary care mental health services
• • Capacity to provide informed consent to engage in therapy
• Exclusion Criteria:
• • Acute risk of harm to self or others
• • Unable to engage in therapy due to language barriers
• • Primary diagnosis of alcohol/substance dependence, learning disability, or organic brain injury or illness implicated in psychosis